Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing–remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study)

[1]  S. Ozakbas,et al.  Effects of Fingolimod on Cognitive Status in Patients with Multiple Sclerosis: Prospective, Controlled Trial (P3.071) , 2016 .

[2]  L. Kappos,et al.  Fingolimod Effects on PASAT Score and Baseline Determinants of PASAT in a Large Cohort of RRMS Patients (P2.150) , 2016 .

[3]  J. Bowen,et al.  The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis , 2015, CNS Drugs.

[4]  J. Fonseca.  Fingolimod Real World Experience: Efficacy and Safety in Clinical Practice , 2015, Neuroscience journal.

[5]  P. Rieckmann,et al.  Functional clinical outcomes in multiple sclerosis: Current status and future prospects. , 2015, Multiple sclerosis and related disorders.

[6]  Massimo Filippi,et al.  Clinical and imaging assessment of cognitive dysfunction in multiple sclerosis , 2015, The Lancet Neurology.

[7]  Ludwig Kappos,et al.  Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis , 2015, Neurology.

[8]  Hirofumi Ochi,et al.  [Cognitive impairment in multiple sclerosis]. , 2014, Brain and nerve = Shinkei kenkyu no shinpo.

[9]  Jeffrey A. Cohen,et al.  Defining the clinical course of multiple sclerosis: the 2013 revisions. , 2014, Neurology.

[10]  P. Hämäläinen,et al.  Neuropsychological rehabilitation for multiple sclerosis. , 2014, The Cochrane database of systematic reviews.

[11]  H. Wiendl,et al.  Clinical Relevance of Brain Volume Measures in Multiple Sclerosis , 2014, CNS Drugs.

[12]  J. DeLuca,et al.  Treatment of cognitive impairment in multiple sclerosis: position paper , 2013, Journal of Neurology.

[13]  F. Patti.  Treatment of cognitive impairment in patients with multiple sclerosis , 2012, Expert opinion on investigational drugs.

[14]  H. Hartung,et al.  Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) , 2012, Multiple sclerosis.

[15]  M. Sá,et al.  Cognitive Dysfunction in Multiple Sclerosis , 2012, Front. Neur..

[16]  A. Giorgio,et al.  Association of MRI metrics and cognitive impairment in radiologically isolated syndromes , 2012, Neurology.

[17]  Jeffrey A. Cohen,et al.  Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.

[18]  Vicente Belloch,et al.  Anatomical and functional differences between the Paced Auditory Serial Addition Test and the Symbol Digit Modalities Test , 2011, Journal of clinical and experimental neuropsychology.

[19]  S. Rombouts,et al.  The contribution of MRI in assessing cognitive impairment in multiple sclerosis , 2010, Neurology.

[20]  Ludwig Kappos,et al.  A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. , 2010, The New England journal of medicine.

[21]  Ludwig Kappos,et al.  Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. , 2010, The New England journal of medicine.

[22]  M. Trojano,et al.  Effects of immunomodulatory treatment with subcutaneous interferon beta-1a oncognitive decline in mildly disabled patients with relapsing—remitting multiple sclerosis , 2010, Multiple sclerosis.

[23]  F. Paul,et al.  Poor PASAT performance correlates with MRI contrast enhancement in multiple sclerosis , 2009, Neurology.

[24]  Massimo Filippi,et al.  Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. , 2009, Archives of neurology.

[25]  L. Pollak,et al.  Cognitive dysfunction evaluation in multiple sclerosis patients treated with interferon beta-1b: an open-label prospective 1 year study. , 2007, The Israel Medical Association journal : IMAJ.

[26]  R. Benedict,et al.  Validity of the Wisconsin Card Sorting and Delis–Kaplan Executive Function System (DKEFS) Sorting Tests in multiple sclerosis , 2007, Journal of clinical and experimental neuropsychology.

[27]  Emilio Portaccio,et al.  Multiple sclerosis-related cognitive changes: A review of cross-sectional and longitudinal studies , 2006, Journal of the Neurological Sciences.

[28]  Ludwig Kappos,et al.  A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[29]  S. Reingold,et al.  Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” , 2005, Annals of neurology.

[30]  Edith Kaplan,et al.  Reliability and validity of the Delis-Kaplan Executive Function System: An update , 2004, Journal of the International Neuropsychological Society.

[31]  A. Achiron,et al.  Effect of Interferon-beta-1b on Cognitive Functions in Multiple Sclerosis , 2002, European Neurology.

[32]  J. Ruutiainen,et al.  The progress of cognitive decline in multiple sclerosis. A controlled 3-year follow-up. , 1997, Brain : a journal of neurology.

[33]  M. Åsberg,et al.  A New Depression Scale Designed to be Sensitive to Change , 1979, British Journal of Psychiatry.

[34]  F. Mattioli,et al.  The Rao’s Brief Repeatable Battery version B: normative values with age, education and gender corrections in an Italian population , 2013, Neurological Sciences.

[35]  J. Abraham.  The international conference on harmonisation of technical requirements for registration of pharmaceuticals for human use , 2009 .

[36]  A. Traboulsee,et al.  The role of MRI in the diagnosis of multiple sclerosis. , 2006, Advances in neurology.

[37]  J. Ridley.  Studies of Interference in Serial Verbal Reactions , 2001 .

[38]  Ethical principles for medical research involving human subjects. , 2001, European journal of emergency medicine : official journal of the European Society for Emergency Medicine.

[39]  Pharmaceutical Development.  INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE , 1998 .